ID
28265
Description
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Visit: End of Treatment. Quelle: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz
Keywords
Versions (2)
- 12/7/17 12/7/17 -
- 1/1/18 1/1/18 -
Copyright Holder
Prof. Dr. med. Georg Heß
Uploaded on
January 1, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
End of Treatment GOAL Trial B-cell Lymphoma NCT02499003
End of Treatment GOAL Trial B-cell Lymphoma NCT02499003
- StudyEvent: ODM
Similar models
End of Treatment GOAL Trial B-cell Lymphoma NCT02499003
- StudyEvent: ODM
C0242656 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,2])
C0011065 (UMLS CUI [1,2])
C1707492 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
C1299582 (UMLS CUI [1,4])
No comments